University of Wisconsin, Madison
wisc.eduTotal trials
1,154
Active
213
Phase 3
29
Total enrollment
2,580,300
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 91 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nicotine patch | — | — | — | — | 12 | ||
| Varenicline | — | — | — | — | — | 7 | |
| Paclitaxel | — | — | — | — | 4 | ||
| Nicotine Pouches | — | — | — | — | — | 1 | |
| Mini Nicotine lozenges | — | — | — | — | — | 1 | |
| TAP Anesthesia | — | — | — | — | — | 1 | |
| Surgeon-Initiated Local Anesthetic | — | — | — | — | — | 1 | |
| Envarsus XR | — | — | — | — | 2 | ||
| Letermovir | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 4 | |
| Pembrolizumab | — | — | 6 | ||||
| Cetuximab | — | — | — | — | 4 | ||
| Bevacizumab | — | — | — | — | — | 4 | |
| Prazosin | — | — | — | — | — | 3 | |
| pTVG-HP | — | — | — | — | — | 3 | |
| pTVG-AR | — | — | — | — | 3 | ||
| 18F-fluorofuranylnorprogesterone | — | — | — | — | — | 2 | |
| Saline | — | — | — | — | 2 | ||
| Prednisone | — | — | — | — | 3 | ||
| Anastrozole | — | — | — | — | 2 | ||
| Tranexamic Acid | — | — | — | — | 2 | ||
| hu14.18-IL2 | — | — | — | — | 3 | ||
| Doxorubicin | — | — | — | — | — | 3 | |
| Pegfilgrastim | — | — | — | — | 3 | ||
| Panitumumab | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | — | — | 2 | |
| Vincristine | — | — | — | — | — | 2 | |
| Degarelix | — | — | — | — | 2 | ||
| Celecoxib | — | — | — | — | — | 2 | |
| GM-CSF | — | — | — | — | 2 | ||
| Irinotecan | — | — | — | — | — | 1 | |
| FOLFIRI Protocol | — | — | — | — | — | 1 | |
| Nal-IRI | — | — | — | — | — | 1 | |
| 5-FU | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| 18F-DCFPyL | — | — | — | — | — | 1 | |
| FDA-approved gadolinium-based intravenous contrast agent | — | — | — | — | — | 1 | |
| FAPI tracer | — | — | — | — | — | 1 | |
| Liposomal irinotecan | — | — | — | — | — | 1 | |
| TAS102 | — | — | — | — | — | 1 |
51 more active programs hidden
Next readouts
- 2022-11-22
- 2022-12-05
- 2024-01-06
- 2024-04-18
- 2024-11-24
- 2025-01-13
- 2025-12-09
- 2026-04
- 2026-06
- 2026-06
Top conditions
- Breast Cancer33
- Prostate Cancer31
- Healthy27
- Obesity27
- Smoking26
- Smoking Cessation26
- Nicotine Dependence20
- Asthma18
Frequently asked questions about University of Wisconsin, Madison
- How many clinical trials does University of Wisconsin, Madison have on ClinicalTrials.gov?
- University of Wisconsin, Madison is listed as the lead sponsor on 1,154 clinical trials in ClinicalTrials.gov, 213 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Wisconsin, Madison's trials are in Phase 3?
- 29 of University of Wisconsin, Madison's trials are in Phase 3, spread across 91 active drug programs.
- What therapeutic areas does University of Wisconsin, Madison focus on?
- University of Wisconsin, Madison's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Healthy, Obesity, Smoking.
- When are University of Wisconsin, Madison's next clinical trial readouts?
- University of Wisconsin, Madison has 10 upcoming primary-completion readouts tracked here; the soonest is “MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer”, expected around 2022-11-22.